Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug
August 07, 2023 at 10:52 AM EDT
The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder.
